{'fraction_non_alphanumeric': 0.024344569288389514, 'fraction_numerical': 0.0, 'mean_word_length': 5.772151898734177, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The effects of moxaverine on ocular blood flow in patients with age‐related macular degeneration or primary open angle glaucoma and in healthy control subjects

Purpose:  The phosphodiesterase inhibitor moxaverine has been shown to increase choroidal blood flow (BF) in young healthy subjects. The present study was performed to investigate the effect of intravenously administered moxaverine on ocular BF in patients with age‐related macular degeneration (AMD), primary open angle glaucoma (POAG) and in age‐matched control subjects.